Area of research
Endocrinology, Diabetes and Metabolism · Nephrology
Research interest
Research interests include Diabetes Treatment and Management, Chronic Kidney Disease and Diabetes, Heart Failure Treatment and Management, and Metabolism, Diabetes, and Cancer.
Effects of Semaglutide With or Without Concomitant Mineralocorticoid Receptor Antagonist Use in Participants With Type 2 Diabetes and Chronic Kidney Disease: A FLOW Trial Prespecified Secondary Analysis
FLOW: Effects of Semaglutide on Kidney Failure Using the Kidney Failure Risk Equation
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial
Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial
Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial
The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER
Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial
Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease
Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the <scp>LEADER</scp> randomized trial
MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS
TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6
Hemoglobin A1c Reduction with the GLP-1 Receptor Agonist Semaglutide Is independent of Baseline eGFR: Post Hoc Analysis of SUSTAIN and PIONEER Programs
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events
FP482EGFR LOSS WITH GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUE TREATMENT: DATA FROM SUSTAIN 6 AND LEADER
FP483EFFECTS OF SEMAGLUTIDE AND LIRAGLUTIDE ON URINARY ALBUMIN-TO-CREATININE RATIO (UACR) – A POOLED ANALYSIS OF SUSTAIN 6 AND LEADER
Response by Mann et al to Letter Regarding Article, “Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial”
SaO010EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) ANALOGUES SEMAGLUTIDE AND LIRAGLUTIDE ON RENAL OUTCOMES – A POOLED ANALYSIS OF THE SUSTAIN 6 AND LEADER TRIALS
Der kardiovaskuläre Effekt von Liraglutid in der LEADER-Studie bleibt erhalten bei erstem und wiederauftretenden MACE
Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease